Development of a magnetite-gene complex for gene
transfection

doi:10.1007/s11684-010-0032-7

Front. Med.

2010, Vol. 4

Issue (2) : 241-246 https://doi.org/10.1007/s11684-010-0032-7

Research articles

Development of a magnetite-gene complex for gene transfection

Jian XIN BM¹,Ze-Feng XIA MD¹,Kai-Xiong TAO MD¹,Kai-Lin CAI PhD¹,Gao-Xiong HAN MD¹,Xiao-Ming SHUAI MD¹,Ji-Liang WANG MD¹,Han-Song DU MD¹,Guo-Bin WANG PhD¹,Yan LUO MM²,

1.Department of Laparoscopic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; 2.Department of Ophthalmology, Wuhan No. 1 Hospital, Wuhan 430022, China;

Download: PDF(250 KB)
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract The key to successful gene therapy is to find a suitable method and carrier for transfection to allow a gene to be transferred into a cell and integrated into the target gene. The aim of this study was to determine whether biomagnetic material could be combined with the nucleic acid for gene transfection. Dextran-coated iron oxide nanoparticles (DCIONPs) were prepared and mixed with the plasmid pGenesil-1 containing the test gene, which expresses enhanced green fluorescent protein (eGFP). PGenesil-1 empty vector was used as a control. The binding ability was assessed by electrophoresis of the DNA on agarose gels and quantification using BANDSCAN software. Using different gene carriers, Lipofectamine 2000, Sofast, and DCIONPs, the large intestine cancer (Lovo) cell line was transfected in vitro with or without a magnetic field. The expression of eGFP was observed by fluorescence microscopy, and the transfection efficiency was compared. The results showed there was a rapid increase in combining rate when the quality ratio of DCIONPs and pGenesil-1 ascended from 1∶1 to 5∶1. However, the combining rate increased less rapidly as the quality ratio continued ascending. The expression of eGFP showed that the early transfection rate could be improved by applying a magnetic field. In conclusion, the DCIONPs we synthesized are able to carry plasmid DNA and enhance the early transfection efficiency when using a magnetic field.

Keywords nanoparticle magnetite gene therapy magnetofection

Issue Date: 05 June 2010

Cite this article:

Jian XIN BM,Kai-Xiong TAO MD,Ze-Feng XIA MD, et al. Development of a magnetite-gene complex for gene transfection[J]. Front. Med., 2010, 4(2): 241-246.

URL:

https://academic.hep.com.cn/fmd/EN/10.1007/s11684-010-0032-7
https://academic.hep.com.cn/fmd/EN/Y2010/V4/I2/241

	Williams D A. Gene therapy continues tomature and to face challenges. Mol Ther, 2009, 17(8): 1305–1306 doi: 10.1038/mt.2009.162
	Khalil I A, Kogure K, Futaki S, Hama S, Akita H, Ueno M, Kishida H, Kudoh M, Mishina Y, Kataoka K, Yamada M, Harashima H. Octaarginine-modified multifunctional envelope-type nanoparticlesfor gene delivery. Gene Ther, 2007, 14(8): 682–689 doi: 10.1038/sj.gt.3302910
	Gopenath P, Gogoi S K, Chattopadhyay A, Ghosh S S. Implication of silver nanoparticle induced cell apoptosisfor in vitro gene therapy. Nanotechnology, 2008, 19(7): 1–10
	Goetze T, Gansau C, Buske N, Roeder M, Gornert P, Bahr M. Biocompatible magnetic core/shellnanoparticles. J Magn Magn Mater, 2002, 252 (1―3): 399–402 doi: 10.1016/S0304-8853(02)00624-8
	Wang G B, Xia Z F, Tao K X, Zhou L G, Liu J W, Xiao Y, Li J X. Experimental study on acute toxicology of Fe3O4 nano-magnetic ferrifluid. Huazhong Ke Ji Da Xue Xue Bao (Yi Xue Ban), 2004, 33(4): 452–454 (in Chinese)
	Lubbe A S, Alexiou C, Bergemann C. Clinical applications ofmagnetic drug targeting. J Surg Res, 2001, 95(2): 200–206 doi: 10.1006/jsre.2000.6030
	Tao K X, Chen D D, Wang G B, Bai Z J, Lu X M, Tian Y, Wu Z D, Hu F X, Niu X. Experimental study and clinical application of magnetic adriamycin-protein microspherestargeting therapy on gastric cancer. Zhonghua Wai Ke Za Zhi, 1999, 37(4): 205–207 (in Chinese)
	Krotz F, de Wit C, Sohn H Y, Zahler S, Gloe T, Pohl U, Plank C. Magnetofection–ahighly efficient tool for antisense oligonucleotide delivery in vitroand in vivo. Mol Ther, 2003, 7(5 Pt 1): 700–710 doi: 10.1016/S1525-0016(03)00065-0
	Xia Z F, Wang G B, Tao K X, Li J X. Preparation of magnetite-dextran microspheres by ultrasonication. J Magn Magn Mater, 2005, 293(1): 182–186 doi: 10.1016/j.jmmm.2005.01.059
	Telang W, Ertl H C J. Immune barriers to successful gene therapy. Trends Mol Med, 2009, 15(1): 32–39 doi: 10.1016/j.molmed.2008.11.005
	Knowles M R, Hohneker K W, Zhou Z, Olsen J C, Noah T L, Hu P C, Leigh M W, Engelhardt J F, Edwards L J, Jones K R, Grossman M, Wilson J M, Johnson L G, Boucher R C. A controlled study of adenoviral-vector-mediated genetransfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med, 1995, 333(13): 823–831 doi: 10.1056/NEJM199509283331302
	Takahashi Y, Nishikawa M, Takakura Y. Nonviral vector-mediatedRNA interference: its gene silencing characteristics and importantfactors to achieve RNAi-based gene therapy. Adv Drug Deliv Rev, 2009, 61(9): 760–766 doi: 10.1016/j.addr.2009.04.006
	Lubbe A S, Bergemann C, Riess H, Schriever F, Reichardt P, Possinger K, Matthias M, Dorken B, Herrmann F, Gurtler R, Hohenberger P, Haas N, Sohr R, Sander B, Lemke A J, Ohlendorf D, Huhnt W, Huhn D. Clinical experiences with magnetic drugtargeting: a phase I study with 4'-epidoxorubicin in 14 patients withadvanced solid tumors. Cancer Res, 1996, 56(20): 4686–4693
	Wagner S, Schnorr J, Pilgrimm H, Hamm B, Tarpitz M. Monomer-coated very small superparamagnetic iron oxide particles as contrast mediumfor magnetic resonance imaging: preclinical in vivo characterization. Invest Radiol, 2002, 37(4): 167–177 doi: 10.1097/00004424-200204000-00002
	Scherer F, Anton M, Schillinger U, Henke J, Bergemann C, Kruger A, Gansbacher B, Plank C. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro andin vivo. Gene Ther, 2002, 9(2): 102–109 doi: 10.1038/sj.gt.3301624
	Xiang J J, Zhu S G, Lv H B, Ruan J M, Zhang B C, Li J, Li G Y. Use of magnetic iron oxide nanoparticles as gene carrier. Ai Zheng, 2001, 20(10): 1009–1014 (in Chinese)
	Bergemann C, Muller-Schulte D, Oster J, a Brassard L, Lubbe A S. Magnetic ion-exchange nano- and microparticles for medical, biomedical andmolecular biological applications. J Magn Magn Mater, 1999, 194: 45–52 doi: 10.1016/S0304-8853(98)00554-X
	Plank C, Schillinger U, Scherer F, Bergemann C, Remy J S, Krotz F, Anton M, Lausier J, Rosenecker J. The magnetofection method: using magnetic force to enhancegene delivery. Biol Chem, 2003, 384(5): 737–747 doi: 10.1515/BC.2003.082
	Mykhaylyk O, Zelphati O, Hammerschmid E, Anton M, Rosenecker J, Plank C. Recent advances in magnetofectionand its potential to deliver siRNAs in vitro. Methods Mol Biol, 2009, 487: 111–146
	Mair L, Ford K, Alam M R, Kole R, Fisher M, Superfine R. Size-uniform 200nm particles: fabrication and applicationto magnetofection. J Biomed Nanotechnol, 2009, 5(2): 182–191 doi: 10.1166/jbn.2009.1024
	Huttinger C, Hirschberger J, Jahnke A, Kostlin R, Brill T, Plank C, Kuchenhoff H, Krieger S, Schillinger U. Neoadjuvant gene delivery of feline granulocyte-macrophagecolony-stimulating factor using magnetofection for the treatment offeline fibrosarcomas: a phase I trial. J Gene Medi, 2008, 10(6): 655–667 doi: 10.1002/jgm.1185

[1]	Yanlin Zhao,Xiao Zhong,Xiaohong Ou,Huawei Cai,Xiaoai Wu,Rui Huang. Cotransfecting norepinephrine transporter and vesicular monoamine transporter 2 genes for increased retention of metaiodobenzylguanidine labeled with iodine 131 in malignant hepatocarcinoma cells[J]. Front. Med., 2017, 11(1): 120-128.
[2]	Wei Lu,Qingzhang Zhou,Hao Yang,Hao Wang,Yexing Gu,Qi Shen,Jinglun Xue,Xiaoyan Dong,Jinzhong Chen. Gene therapy for hemophilia B mice with scAAV8-LP1-hFIX[J]. Front. Med., 2016, 10(2): 212-218.
[3]	Chuanfeng Wu, Cynthia E. Dunbar. Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity[J]. Front Med, 2011, 5(4): 356-371.
[4]	Liangqian Tong, Ming Zhao, Shu Zhu, Jing Chen. Synthesis and application of superparamagnetic iron oxide nanoparticles in targeted therapy and imaging of cancer[J]. Front Med, 2011, 5(4): 379-387.
[5]	Xudong YU MM, Zengwu SHAO MD, Liming XIONG MD, Weiwei XU MM, Hezhong WANG MM, Huifa XU MM, . Adenovirus-mediated tissue inhibitor of metalloproteinase-3 gene transfection inhibits rabbit intervertebral disc degeneration in vivo[J]. Front. Med., 2009, 3(4): 415-420.
[6]	Youguo HAO, Min ZHANG, Jinzhi XU, Bitao BU, Jiajun WEI. Construction of lentiviral vector carrying Rab9 gene and its expression in mouse brain[J]. Front Med Chin, 2009, 3(2): 141-147.
[7]	XIA Xi, WANG Beibei, CAO Li, CHEN Gang, WU Peng, LU Yunping, ZHOU Jianfeng, MA Ding. Investigation of gene therapy of denovirus in immune suppression[J]. Front. Med., 2008, 2(4): 386-390.
[8]	XIONG Ying, GUO Wen, LI Ting, LI Ke. Influence of Survivin-targeted siRNA on the biological features of colorectal carcinoma cells[J]. Front. Med., 2007, 1(3): 304-307.
[9]	TIAN Yongji, LI Guilin, GAO Jun, WANG Renzhi, KONG Yanguo, ZHANG Zhenxing, LI Shifang, TIAN Shiqiang, DOU Wanchen, ZHANG Bo. Construction of 6HRE-GFAP-Baxα system specific for glioma gene therapy[J]. Front. Med., 2007, 1(1): 49-53.

Viewed

Full text

Abstract

Cited

Shared

Discussed